Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Bought by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 55.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 33,189 shares of the medical equipment provider's stock after buying an additional 11,798 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in Lantheus were worth $2,969,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of LNTH. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus in the third quarter valued at approximately $25,000. Kestra Investment Management LLC bought a new stake in Lantheus during the 4th quarter valued at $27,000. Summit Securities Group LLC purchased a new stake in shares of Lantheus in the 4th quarter worth $37,000. UMB Bank n.a. grew its position in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after buying an additional 134 shares in the last quarter. Finally, Parkside Financial Bank & Trust increased its stake in shares of Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after buying an additional 280 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Price Performance

LNTH stock traded down $1.87 during trading on Friday, hitting $101.77. 644,509 shares of the company traded hands, compared to its average volume of 955,167. Lantheus Holdings, Inc. has a 1 year low of $65.76 and a 1 year high of $126.89. The stock's 50-day simple moving average is $97.37 and its 200 day simple moving average is $95.23. The company has a market cap of $6.97 billion, a PE ratio of 16.93 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. Research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Activity

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock worth $6,016,046 over the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial upped their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Finally, B. Riley cut their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.